SCHEMBL25257220

SCHEMBL25257220

Cc1cc(C(=O)Nc2cc(N)ccc2C)no1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.56
NPC1 O15118 6/20 0.55
RAB9A P51151 5/20 0.55
ALDH1A1 P00352 4/20 0.55
HTT P42858 2/20 0.55
TP53 P04637 2/20 0.55
GLA P06280 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.52
ATM Q13315 1/20 0.51
KDM4E B2RXH2 1/20 0.51
HPGD P15428 1/20 0.51
SMN1; SMN2 Q16637 5/20 0.50
GAA P10253 2/20 0.50
STAT3 P40763 1/20 0.50
AGTR1 P30556 1/20 0.50
NFKB1 P19838 1/20 0.50
NFKB2 Q00653 1/20 0.50
RELA Q04206 1/20 0.50
USP2 O75604 1/20 0.50
HSD17B10 Q99714 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19376953 0.89 MAPT (0.57) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL25534280 0.84 SMN1; SMN2 (0.50) MAPTNPC1RAB9AALDH1A1TP53
SCHEMBL8266861 0.81 NPC1 (0.77) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL25235561 0.79 MAPT (0.67) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL8267184 0.79 HTT (0.74) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL8267411 0.78 HTT (0.65) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL12192578 0.77 ALDH1A1 (0.67) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL8267156 0.77 SMN1; SMN2 (0.72) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL9817347 0.77 GAA (0.74) MAPTNPC1RAB9AALDH1A1HTT
SCHEMBL5503938 0.76 LCK (0.48) MAPTNPC1RAB9AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240308994-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2024-09-19 US disclosed
WO-2023096304-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 한양대학교 에리카산학협력단 2023-06-01 WO disclosed
WO-2023096304-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF 한양대학교 에리카산학협력단 2023-06-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308994-A1 ISOXAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND USE THEREOF CSF1R, CSF3R, IL15RA MAPT 203/4885NPC1 722/4885RAB9A 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.